Cargando…

Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence

Several novel treatments for chronic lymphocytic leukemia (CLL) have been recently approved based on the results of randomized clinical trials. However, real-world evidence (RWE) is also requested before and after drug authorization in order to confirm safety and to provide data for health technolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchetti, Monia, Vitale, Candida, Rigolin, Gian Matteo, Vasile, Alessandra, Visentin, Andrea, Scarfò, Lydia, Coscia, Marta, Cuneo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028394/ https://www.ncbi.nlm.nih.gov/pubmed/35456167 http://dx.doi.org/10.3390/jcm11082076

Ejemplares similares

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?
por: Cuneo, Antonio, et al.
Publicado: (2021)

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report
por: Cuneo, Antonio, et al.
Publicado: (2020)

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
por: Perutelli, Francesca, et al.
Publicado: (2022)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?
por: Vitale, Candida, et al.
Publicado: (2023)

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups
por: Cuneo, Antonio, et al.
Publicado: (2014)

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12
por: Autore, Francesco, et al.
Publicado: (2019)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
por: Scarfò, Lydia, et al.
Publicado: (2019)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
por: Rigolin, Gian Matteo, et al.
Publicado: (2023)

Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
por: Vitale, Candida, et al.
Publicado: (2020)

Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia
por: Vitale, Candida, et al.
Publicado: (2021)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
por: Cavallari, Maurizio, et al.
Publicado: (2017)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences
por: Vitale, Candida, et al.
Publicado: (2020)

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
por: Mauro, Francesca R., et al.
Publicado: (2023)

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
por: Agnoletto, Chiara, et al.
Publicado: (2014)

The p53 transcriptional pathway is preserved in ATM(mutated) and NOTCH1(mutated) chronic lymphocytic leukemias
por: Athanasakis, Emmanouil, et al.
Publicado: (2014)

The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
por: Visentin, Andrea, et al.
Publicado: (2021)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients
por: De Matteis, Serena, et al.
Publicado: (2018)

COVID-19 prophylaxis: half-full or half-empty glass?
por: Scarfò, Lydia, et al.
Publicado: (2023)

Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia
por: Cavallari, Maurizio, et al.
Publicado: (2018)

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
por: Vitale, Candida, et al.
Publicado: (2023)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
por: Cuneo, Antonio, et al.
Publicado: (2020)

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

Statin Therapy in Very Old Patients: Lights and Shadows
por: Cobos-Palacios, Lidia, et al.
Publicado: (2021)

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
por: Innocenti, Idanna, et al.
Publicado: (2022)

Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
por: Cafforio, Luciana, et al.
Publicado: (2021)

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
por: Peragine, Nadia, et al.
Publicado: (2020)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022)

Delirium in acute promyelocytic leukemia patients: two case reports
por: Rigolin, Gian Matteo, et al.
Publicado: (2013)

Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study
por: Visentin, Andrea, et al.
Publicado: (2020)

Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis
por: Marchetti, Monia, et al.
Publicado: (2022)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8akervo2kpmt3nhk4fnvq7kbng